Literature DB >> 2862574

Brain nicotinic acetylcholine receptors. Biochemical characterization by neosurugatoxin.

S Yamada, M Isogai, Y Kagawa, N Takayanagi, E Hayashi, K Tsuji, T Kosuge.   

Abstract

Specific [3H]nicotine binding to rat forebrain membranes was saturable and of high affinity, and it exhibited pharmacological specificity as well as stereoselectivity for nicotinic agents. There was a regional variation of specific [3H]nicotine binding in rat brain. Low concentrations of neosurugatoxin markedly inhibited specific [3H]nicotine binding in rat forebrain (IC50 = 78 nM) and the competition curve by the toxin was biphasic (pseudo-Hill slope, 0.44). Approximately 50% of [3H]nicotine binding in rat forebrain was inhibited by low concentrations (0.3-100 nM) of neosurugatoxin and the residual binding was inhibited by higher concentrations (0.3-10 microM). In the presence of 3 nM, 100 nM, and 1 microM neosurugatoxin, there was a concentration-dependent (28, 54, and 71%, respectively) loss of [3H]nicotine-binding sites (Bmax) in rat forebrain with little change in the dissociation constant (Kd). The blockade of brain [3H]nicotine-binding sites induced by neosurugatoxin was not reversed by washing. Further, the toxin (10 microM) considerably accelerated the dissociation of [3H]nicotine from its receptor sites initiated by nonlabeled (-)nicotine. These observations suggest that neosurugatoxin may allosterically regulate [3H]nicotine binding rather than competing directly. In contrast to a marked inhibition of [3H]nicotine binding, neosurugatoxin (100 nM-10 microM) had no effect on brain [3H]quinuclidinyl benzilate binding. In conclusion, the present study has shown that [3H]nicotine selectively labels nicotinic cholinergic receptors in rat brain and that neosurugatoxin is a potent noncompetitive antagonist of these receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862574

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

2.  The effects of neosurugatoxin on evoked catecholamine secretion from bovine adrenal chromaffin cells.

Authors:  J E Bourke; S J Bunn; P D Marley; B G Livett
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

3.  Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.

Authors:  Kazufumi Hirano; Ryohei Kimura; Yumi Sugimoto; Jun Yamada; Shinya Uchida; Yasuhiro Kato; Hisakuni Hashimoto; Shizuo Yamada
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 4.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

5.  Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats.

Authors:  S Yamada; Y Matsuoka; R Kimura
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

6.  The effect of neosurugatoxin on the release of neurohypophysial hormones by nicotine, hypotension and an osmotic stimulus in the rat.

Authors:  G W Bisset; K M Fairhall; K Tsuji
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

7.  PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo.

Authors:  H Nybäck; C Halldin; A Ahlin; M Curvall; L Eriksson
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

8.  Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.

Authors:  Shizuo Yamada; Shiori Kuraoka; Ayaka Osano; Yoshihiko Ito
Journal:  Int Neurourol J       Date:  2012-09-30       Impact factor: 2.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.